The stock of Epizyme Inc (NASDAQ:EPZM) is a huge mover today! The stock increased 7.83% or $0.85 on November 23, hitting $11.7. About 243,749 shares traded hands. Epizyme Inc (NASDAQ:EPZM) has declined 7.07% since April 22, 2016 and is downtrending. It has underperformed by 12.48% the S&P500.
The move comes after 9 months positive chart setup for the $651.70 million company. It was reported on Nov, 24 by Barchart.com. We have $12.40 PT which if reached, will make NASDAQ:EPZM worth $39.10 million more.
Analysts await Epizyme Inc (NASDAQ:EPZM) to report earnings on March, 8. They expect $-0.62 EPS, down 16.98% or $0.09 from last year’s $-0.53 per share. After $-0.42 actual EPS reported by Epizyme Inc for the previous quarter, Wall Street now forecasts 47.62% negative EPS growth.
Epizyme Inc (NASDAQ:EPZM) Ratings Coverage
Out of 7 analysts covering Epizyme (NASDAQ:EPZM), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $42 is the highest target while $17 is the lowest. The $27.17 average target is 132.22% above today’s ($11.7) stock price. Epizyme has been the topic of 9 analyst reports since August 6, 2015 according to StockzIntelligence Inc. H.C. Wainwright upgraded Epizyme Inc (NASDAQ:EPZM) on Monday, March 14 to “Buy” rating. The rating was downgraded by Zacks on Tuesday, August 25 to “Buy”. The firm earned “Buy” rating on Thursday, August 6 by Mizuho. On Monday, September 28 the stock rating was maintained by RBC Capital Markets with “Outperform”. Mizuho maintained Epizyme Inc (NASDAQ:EPZM) rating on Tuesday, May 10. Mizuho has “Buy” rating and $18 price target. The rating was initiated by Citigroup with “Buy” on Tuesday, April 5. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”.
According to Zacks Investment Research, “Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.09 in Q2 2016. Its down 0.55, from 1.64 in 2016Q1. The ratio dived, as 8 funds sold all Epizyme Inc shares owned while 20 reduced positions. 14 funds bought stakes while 32 increased positions. They now own 45.74 million shares or 3.00% more from 44.40 million shares in 2016Q1.
The New York-based Secor Limited Partnership has invested 0.08% in Epizyme Inc (NASDAQ:EPZM). Qs Invsts Lc last reported 94,526 shares in the company. Century Cos Incorporated reported 50,604 shares or 0% of all its holdings. Swiss Bancorporation last reported 0% of its portfolio in the stock. Renaissance Techs Ltd Com holds 0% or 15,088 shares in its portfolio. Dekabank Deutsche Girozentrale last reported 33,100 shares in the company. Credit Suisse Ag reported 54,530 shares or 0% of all its holdings. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Epizyme Inc (NASDAQ:EPZM) for 422 shares. State Board Of Administration Of Florida Retirement Sys reported 15,347 shares or 0% of all its holdings. Metropolitan Life Insur Co Ny holds 31,085 shares or 0% of its portfolio. Wells Fargo Com Mn has invested 0% of its portfolio in Epizyme Inc (NASDAQ:EPZM). First Republic Investment, a California-based fund reported 15,856 shares. Loring Wolcott & Coolidge Fiduciary Advsr Ltd Liability Partnership Ma holds 0% or 3,000 shares in its portfolio. Palo Alto Lc reported 2.71 million shares or 2.1% of all its holdings. Tocqueville Asset Mngmt Lp has 0% invested in the company for 25,000 shares.
Insider Transactions: Since June 9, 2016, the stock had 0 buys, and 8 insider sales for $141,970 net activity. $9,166 worth of shares were sold by Singer Andrew E. on Tuesday, August 9. The insider Copeland Robert A sold 4,000 shares worth $40,128.
Another recent and important Epizyme Inc (NASDAQ:EPZM) news was published by Fool.com which published an article titled: “Why Epizyme Inc, Akebia Therapeutics Inc, and Cempra Inc Got Wacked Today” on January 07, 2016.
EPZM Company Profile
Epizyme, Inc., incorporated on November 1, 2007, is a clinical-stage biopharmaceutical company. The Firm discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. The Firm develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. The Firm develops small molecule inhibitors of other chromatin modifying proteins, or CMPs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.